Dr. Ryan Cassaday’s research interests and clinical practice are almost exclusively devoted to adults with acute lymphoblastic leukemia, or ALL. He is the principal investigator on investigator-initiated and industry-sponsored clinical trials in adult ALL. He is particularly interested in developing novel chemotherapy strategies for high-risk populations, including older adults and those with relapsed/refractory disease, as well as in using measurable residual disease as a risk-stratification tool — to help distinguish between higher- and lower-risk forms of ALL — in both standard and investigational therapies.